Septerna, Inc. Common Stock logo

Septerna, Inc. Common Stock(SEPN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
WEAK BUY
BUY for 14 days
PROFIT SINCE LAST BUY
-3.49% ▼
LAST CLOSE
$42.6
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SEPN

11/13/2026: SEPN (5-star) is a REGULAR-BUY. BUY for 14 days. Simulated Profits (-3.49%). Updated daily EoD!

Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small molecule drugs targeting GPCRs via its proprietary Native Complex platform. Its main strength lies in a unique scientific approach that seeks to tackle historically difficult biological targets, potentially offering a major improvement over existing injectable treatments. The primary investment story centers on the success of its lead program, SEP-786, and the scalability of its discovery platform. However, as an early-stage company, it faces significant risks including clinical trial uncertainty and heavy reliance on future capital infusions. The stock may suit growth-oriented investors with high risk tolerance who are looking for exposure to novel drug discovery.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high growth potential linked to clinical success but carries extreme binary risk.
Momentum investorMixed fitMomentum may track clinical trial news, but the stock lacks the trading history required for consistent signals.
Value investorWeak fitThere are no earnings or cash flows to support a traditional value-based investment thesis.
Dividend investorWeak fitThe company does not pay a dividend and is unlikely to do so in the near future.
Low-risk investorWeak fitBiotechnology development carries high volatility and the potential for total loss of capital.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical trial results can cause significant, rapid shifts in stock valuation.
Valuation riskHighValuations are speculative and rely heavily on future, unproven clinical outcomes.
Competition riskMedium / highEstablished players in the GPCR space may develop superior or faster-to-market solutions.
Business qualityMediumThe company relies on a single proprietary platform to drive value, concentrating R&D risk.
Dividend incomeLow / noneThe business model prioritizes cash burn for R&D over shareholder distributions.
Execution riskHighThe ability to successfully navigate clinical and regulatory pathways is uncertain.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.03B USD
Price to earnings Ratio -
1Y Target Price 59.22
Price to earnings Ratio -
1Y Target Price 59.22
Volume (30-day avg) 433.2K shares
Beta 2.2
52 Weeks Range 21.31 - 53.34
Updated Date 11/14/2026
52 Weeks Range 21.31 - 53.34
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.32

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 91.32%
Avg. Invested days 39
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SEPN receives a 3-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SEPN has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+31.9%) and strong cash generation (FCF margin 238.7%) are partially offset by weak profitability (net margin -106.4%), modest insider ownership of 2.89%.

Financial Health Rating

★★★★★
SEPN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 54.4%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is SEPN's strongest growth driver at +4174.5% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+31.9%, solid) and free-cash-flow growth (+257.6%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 100.1% and approximately 57.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.89% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 14.99%
TRV GP V, LLC 13.32%
Driehaus Capital Management LLC 9.50%
TRV GP VI, LLC 9.02%
Samsara BioCapital, LLC 6.75%

Unit Economics (Per $1K Revenue)

★★★★★
SEPN generates approximately $1,000 of gross profit, $-1,758 of operating income, and $2,387 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins and weak cash conversion support a 3-star rating, while capital efficiency is weak.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.02% (Tax Credit)

Quantitative Style Profile

★★★★★
SEPN has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Drug DevelopmentResearch and development of GPCR-targeting oral small molecules.The company currently makes no revenue; it survives on capital raised to fund future drug prospects.

Valuation

Trailing PE -
Forward PE 107.53
Enterprise Value 1.53B
Price to Sales(TTM) 21.04
Enterprise Value 1.53B
Price to Sales(TTM) 21.04
Enterprise Value to Revenue 15.91
Enterprise Value to EBITDA -
Shares Outstanding 47.55M
Shares Floating 27.28M
Shares Outstanding 47.55M
Shares Floating 27.28M
Percent Insiders 2.89
Percent Institutions 100.08

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.